Selected Talks

  1. Improving drug safety assessment
    • National Medicines Symposium, Canberra, May 2016
  2. Heuristics for applying evidence from pharmaceutical trials: use and misuse
    • Grand Rounds, Logan Hospital, May 2016
  3. Evidence, EBM and therapeutic decisions
    • Queensland Branch of SHPA (Continuing Education), April 2016
  4. La Caze A. Improving the assessment of drug saftey: An analysis of the clopidogrel-proton pump inhibitor interaction
    • APSA-ASCEPT Joint Scientific Meeting, Hobart, December 2015
  5. Improving the assessment and communication of drug safety
    • Philosophy of Medicine Roundtable, Bristol, August 2015
  6. Assessing drug safety: Workshop (with Darren Roberts)
    • APSA-ASCEPT Joint Scientific Meeting, Hobart, December 2015
  7. Pharmacy, professional responsibility and complementary medicine (with Priya Iyer and Reanna McFarland)
    • Australasian Pharmaceutical Sciences Association, Brisbane, December 2014
  8. Heuristics for applying evidence in medicine: use and misuse
    • Pharmacy Department, Princess Alexandra Hospital, Brisbane, July 2013
  9. When randomized studies
    • Evidence and Causality in the Sciences, University of Kent, September 2012
    • “The Authority of Science”, 4th Sydney-Tilburg conference on the philosophy of science, University of Sydney, April 2011
  10. Pitfalls of evidence-based medicine in cardiovascular disease
    • Society of Hospital Pharmacists, Cardiology Symposium, June 2011
  11. Large simple trials and therapeutic decisions
    • Philosophy of Medicine Roundtable, San Sebastian, November 2011
  12. Standards of Evidence and the Ethics of Randomised Trials
    • Third International Workshop, Philosophy of Medicine, Madrid, November 2011
    • Australian Association of Professional and Applied Ethics, University of Sydney, June 2010
  13. The role of basic science in evidence based medicine
    • Mechanisms and Causality in the Sciences, University of Kent, September 2009
    • Sydney-Tilburg Conference on Evidence, Science and Public Policy, University of Sydney, March 2009
  14. Power, estimation and inference: The Rofecoxib Case
    • Philosophy of Medicine Roundtable, University of Alabama at Birmingham, April 2008
  15. A reason why informed consent is impossible (or at least very hard)
    • Australasian Association of Philosophy, Armidale, July 2007
  16. If it is going to make sense, EBM must not be…
    • Evidence in the Humanities Workshop, Biohumanities Project, University of Queensland, Brisbane, January 2007
  17. What’s too subjective about Bayesian statistics?
    • Current Projects. Center for Time, Philosophy Department, University of Sydney, August 2007
  18. Quantifying decision risks when interpreting clinical trials (with Stephen Duffull)
    • Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) New Zealand, August 2006
  19. Inferences from medical trials should be probabilistic
    • Australian Association of Philosophy, Canberra July 2006
  20. Interpreting trials and estimating risk: the rofecoxib case
    • Paper presentation, National Medicines Symposium, Canberra, June 2006
  21. Medicines, genetics and the justification of cost-effectiveness analysis
    • European Commission, Brussels, 2006
  22. What are the epistemic limits of evidence based medicine?
    • Philosophy of Biology Postgraduate Workshop, ANU, December 2005